Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

University of Rochester, Rochester, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Rochester, NY
Treatments:Biologic therapyHospital:University of Rochester
Drugs:Journal:Link
Date:Jul 2015

Description:

Patients:
This phase 2 study involved 37 peripheral T Cell lymphoma patients who had been previously treated. The median patient age was 62 years and 65% were male.

Treatment:
Patients received biologic therapy with alisertib, an oral aurora A kinase (AAK) inhibitor.

Toxicities:
There was one treatment-related death due to grade 5 sepsis (infection). Grade 3 or higher neutropenia, mucositis (inflammation of the lining of the digestive tract), and anemia were also reported.

Results:
The median overall survival was 8 months.

Correspondence: Dr. Paul M. Barr; email: [email protected]



Back